Influence of dietary fat intake on the endocannabinoid system in lean and obese subjects

Obesity

Volumn 22, Issue 5, 2014, Pages

  Engeli, Stefan ^a   Lehmann, Anne Christin ^a   Kaminski, Jana ^b   Haas, Verena ^c   Janke, Jürgen ^d   Zoerner, Alexander A ^a   Luft, Friedrich C ^c   Tsikas, Dimitrios ^a   Jordan, Jens ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b UNIVERSITY OF POTSDAM   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

2 ARACHIDONOYLGLYCEROL; ACYLGLYCEROL LIPASE; ANANDAMIDE; ARACHIDONOYLPHOSPHATIDYLETHANOLAMINE PHOSPHOLIPASE D; CANNABINOID 1 RECEPTOR; DIACYLGLYCEROL LIPASE ALPHA; ENDOCANNABINOID; FATTY ACID AMIDASE; INSULIN; LIPOPROTEIN LIPASE; MESSENGER RNA; PHOSPHOLIPASE D; UNCLASSIFIED DRUG; AMIDASE; AMIDE; ARACHIDONIC ACID DERIVATIVE; DIACYLGLYCEROL LIPASE ALPHA, HUMAN; FAT INTAKE; FATTY-ACID AMIDE HYDROLASE; GLUCOSE BLOOD LEVEL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD LEVEL; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROSSOVER PROCEDURE; DISEASE ASSOCIATION; DOWN REGULATION; ENDOCANNABINOID SYSTEM; FAT INTAKE; FEMALE; GENE EXPRESSION REGULATION; HUMAN; INSULIN BLOOD LEVEL; LEAN BODY WEIGHT; LIPID DIET; LOW FAT DIET; MALE; MASS SPECTROMETRY; NERVOUS SYSTEM; OBESITY; RANDOMIZED CONTROLLED TRIAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; SUBCUTANEOUS FAT; TISSUE SPECIFICITY; TREATMENT DURATION; UPREGULATION; WEIGHT CHANGE; ADMINISTRATION AND DOSAGE; ADOLESCENT; BLOOD; BODY WEIGHT; DIET RESTRICTION; GENETICS; GLUCOSE BLOOD LEVEL; INTERVENTION STUDY; METABOLISM; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AMIDOHYDROLASES; ARACHIDONIC ACIDS; BLOOD GLUCOSE; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-OVER STUDIES; DIET, HIGH-FAT; DIETARY FATS; DOWN-REGULATION; ENDOCANNABINOIDS; FASTING; FEMALE; HUMANS; INTERVENTION STUDIES; LIPOPROTEIN LIPASE; MALE; MIDDLE AGED; MONOACYLGLYCEROL LIPASES; MUSCLE, SKELETAL; OBESITY; POLYUNSATURATED ALKAMIDES; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER; SUBCUTANEOUS FAT; THINNESS; TRIGLYCERIDES; UP-REGULATION; YOUNG ADULT;

EID: 84899961425     PISSN: 19307381     EISSN: 1930739X     Source Type: Journal    
DOI: 10.1002/oby.20728     Document Type: Article

References (39)

1. Engeli S,. Peripheral metabolic effects of endocannabinoids and cannabinoid receptor blockade. Obes Facts 2008; 1: 8-15.
2. Ravinet TC, Arnone M, Delgorge C, Gonalons N, Keane P, Maffrand JP, Soubrie P,. Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003; 284: R345-R353.
3. Cota D, Marsicano G, Tschop M, Grubler Y, Flachskamm C, Schubert M, et al. The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003; 112: 423-431.
4. Ravinet TC, Delgorge C, Menet C, Arnone M, Soubrie P,. CB1 cannabinoid receptor knockout in mice leads to leanness, resistance to diet-induced obesity and enhanced leptin sensitivity. Int J Obes Relat Metab Disord 2004; 28: 640-648.
5. Engeli S,. Central and peripheral cannabinoid receptors as therapeutic targets in the control of food intake and body weight. Handb Exp Pharmacol 2012; 209: 357-381.
6. Tam J, Vemuri VK, Liu J, Batkai S, Mukhopadhyay B, Godlewski G, et al. Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest 2010; 120: 2953-2966.
7. Silvestri C, Di Marzo V,. Second generation CB1 receptor blockers and other inhibitors of peripheral endocannabinoid overactivity and the rationale of their use against metabolic disorders. Exp Opin Investig Drugs 2012; 21: 1309-1322.
8. Sipe JC, Scott TM, Murray S, Harismendy O, Simon GM, Cravatt BF, Waalen J,. Biomarkers of endocannabinoid system activation in severe obesity. PLoS ONE 2010; 5: e8792.
9. Muller TD, Reichwald K, Wermter AK, Bronner G, Nguyen TT, Friedel S, et al. No evidence for an involvement of variants in the cannabinoid receptor gene (CNR1) in obesity in German children and adolescents. Mol Genet Metab 2007; 90: 429-434.
10. Schleinitz D, Carmienke S, Bottcher Y, Tonjes A, Berndt J, Kloting N, et al. Role of genetic variation in the cannabinoid type 1 receptor gene (CNR1) in the pathophysiology of human obesity. Pharmacogenomics 2010; 11: 693-702.
11. Jensen DP, Andreasen CH, Andersen MK, Hansen L, Eiberg H, Borch-Johnsen K, et al. The functional Pro129Thr variant of the FAAH gene is not associated with various fat accumulation phenotypes in a population-based cohort of 5,801 whites. J Mol Med 2007; 85: 445-449.
12. Di Marzo V, Verrijken A, Hakkarainen A, Petrosino S, Mertens I, Lundbom N, et al. Role of insulin as a negative regulator of plasma endocannabinoid levels in obese and nonobese subjects. Eur J Endocrinol 2009; 161: 715-722.
13. Murdolo G, Kempf K, Hammarstedt A, Herder C, Smith U, Jansson PA,: Insulin differentially modulates the peripheral endocannabinoid system in human subcutaneous abdominal adipose tissue from lean and obese individuals. J Endocrinol Invest 2007; 30: RC17-RC21.
14. Matias I, Carta G, Murru E, Petrosino S, Banni S, Di Marzo V,: Effect of polyunsaturated fatty acids on endocannabinoid and N-acyl-ethanolamine levels in mouse adipocytes. Biochim Biophys Acta 2008; 1781: 52-60.
15. Starowicz KM, Cristino L, Matias I, Capasso R, Racioppi A, Izzo AA, Di Marzo V,. Endocannabinoid dysregulation in the pancreas and adipose tissue of mice fed with a high-fat diet. Obesity (Silver Spring) 2008; 16: 553-565.
16. Cravatt BF, Demarest K, Patricelli MP, Bracey MH, Giang DK, Martin BR, Lichtman AH,: Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A 2001; 98: 9371-9376.
17. Osei-Hyiaman D, Depetrillo M, Pacher P, Liu J, Radaeva S, Batkai S, et al. Endocannabinoid activation at hepatic CB(1) receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005; 115: 1298-1305.
18. Engeli S, Bohnke J, Feldpausch M, Gorzelniak K, Janke J, Batkai S, et al. Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005; 54: 2838-2843.
19. Bluher M, Engeli S, Kloting N, Berndt J, Fasshauer M, Batkai S, et al. Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006; 55: 3053-3060.
20. Zoerner AA, Batkai S, Suchy MT, Gutzki FM, Engeli S, Jordan J, Tsikas D,. Simultaneous UPLC-MS/MS quantification of the endocannabinoids 2-arachidonoyl glycerol (2AG), 1-arachidonoyl glycerol (1AG), and anandamide in human plasma: Minimization of matrix-effects, 2AG/1AG isomerization and degradation by toluene solvent extraction. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 883-884: 161-171.
21. Tay J, Brinkworth GD, Noakes M, Keogh J, Clifton PM,. Metabolic effects of weight loss on a very-low-carbohydrate diet compared with an isocaloric high-carbohydrate diet in abdominally obese subjects. J Am Coll Cardiol 2008; 51: 59-67.
22. Brinkworth GD, Noakes M, Buckley JD, Keogh JB, Clifton PM,. Long-term effects of a very-low-carbohydrate weight loss diet compared with an isocaloric low-fat diet after 12 mo. Am J Clin Nutr 2009; 90: 23-32.
23. Matias I, Gonthier MP, Orlando P, Martiadis V, De Petrocellis L, Cervino C, et al. Regulation, function, and dysregulation of endocannabinoids in models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J Clin Endocrinol Metab 2006; 91: 3171-3180.
24. Cote M, Matias I, Lemieux I, Petrosino S, Almeras N, Despres JP, Di Marzo V,. Circulating endocannabinoid levels, abdominal adiposity and related cardiometabolic risk factors in obese men. Int J Obes (Lond) 2007; 31: 692-699.
25. Silvestri C, Di Marzo V,. The endocannabinoid system in energy homeostasis and the etiopathology of metabolic disorders. Cell Metab 2013; 17: 475-490.
26. Gatta-Cherifi B, Matias I, Vallee M, Tabarin A, Marsicano G, Piazza PV, Cota D,. Simultaneous postprandial deregulation of the orexigenic endocannabinoid anandamide and the anorexigenic peptide YY in obesity. Int J Obes (Lond) 2012; 36: 880-885.
27. Monteleone P, Piscitelli F, Scognamiglio P, Monteleone AM, Canestrelli B, Di Marzo V, Maj M,. Hedonic eating is associated with increased peripheral levels of ghrelin and the endocannabinoid 2-arachidonoyl-glycerol in healthy humans: a pilot study. J Clin Endocrinol Metab 2012; 97: E917-E924.
28. Kirkham TC, Williams CM, Fezza F, Di Marzo V,. Endocannabinoid levels in rat limbic forebrain and hypothalamus in relation to fasting, feeding and satiation: stimulation of eating by 2-arachidonoyl glycerol. Br J Pharmacol 2002; 136: 550-557.
29. Pacher P, Batkai S, Kunos G,: The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006; 58: 389-462.
30. D'Eon TM, Pierce KA, Roix JJ, Tyler A, Chen H, Teixeira R,. The role of adipocyte insulin resistance in the pathogenesis of obesity-related elevations in endocannabinoids. Diabetes 2008; 57: 1262-1268.
31. Chaves VE, Frasson D, Kawashita NH,. Several agents and pathways regulate lipolysis in adipocytes. Biochimie 2011; 93: 1631-1640.
32. Crespillo A, Suarez J, Bermudez-Silva FJ, Rivera P, Vida M, Alonso M, et al. Expression of the cannabinoid system in muscle: effects of a high-fat diet and CB1 receptor blockade. Biochem J 2011; 433: 175-185.
33. Johnson GH, Fritsche K,. Effect of dietary linoleic acid on markers of inflammation in healthy persons: a systematic review of randomized controlled trials. J Acad Nutr Diet 2012; 112: 1029-1041.
34. Alvheim AR, Malde MK, Osei-Hyiaman D, Lin YH, Pawlosky RJ, Madsen L, et al. Dietary linoleic acid elevates endogenous 2-AG and anandamide and induces obesity. Obesity (Silver Spring) 2012; 20: 1984-1994.
35. Berge K, Piscitelli F, Hoem N, Silvestri C, Meyer I, Banni S, Di Marzo V,. Chronic treatment with krill powder reduces plasma triglyceride and anandamide levels in mildly obese men. Lipids Health Dis 2013; 12: 78.
36. Hutchins-Wiese HL, Li Y, Hannon K, Watkins BA,. Hind limb suspension and long-chain omega-3 PUFA increase mRNA endocannabinoid system levels in skeletal muscle. J Nutr Biochem 2012; 23: 986-993.
37. Pacher P, Mechoulam R,. Is lipid signaling through cannabinoid 2 receptors part of a protective system? Prog Lipid Res 2011; 0: 193-211.
38. Nomura DK, Morrison BE, Blankman JL, Long JZ, Kinsey SG, Marcondes MC, et al. Endocannabinoid hydrolysis generates brain prostaglandins that promote neuroinflammation. Science 2011; 334: 809-813.
39. Cao Z, Mulvihill MM, Mukhopadhyay P, Xu H, Erdelyi K, Hao E, et al. Monoacylglycerol lipase controls endocannabinoid and eicosanoid signaling and hepatic injury in mice. Gastroenterology 2013; 144: 808-817.